Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma

On May 27, 2020 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported initial data from pivotal Cohort 4 and updated long-term data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma (Press release, Iovance Biotherapeutics, MAY 27, 2020, View Source [SID1234558544]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very pleased to announce our pivotal Cohort 4 early data from the C-144-01 clinical study in advanced melanoma today," said Maria Fardis, Ph.D., President and Chief Executive Officer of Iovance Biotherapeutics. "The data from the first 68 patients in Cohort 4, with a 32.4% overall response rate (ORR) at 5.3 months of median study follow up, is highly consistent with what we have observed in Cohort 2 with comparable study follow up. For Cohort 2, median duration of response has not been reached at 18.7 months of study follow up. Available care for metastatic melanoma patients enrolled into our program is chemotherapy, which has been reported to offer a 4-10% response rate with a very short median duration of response. Together, these early data continue to support the potential benefit of the one-time administration of lifileucel TIL therapy in advanced melanoma patients."

Interim Pivotal Cohort 4 Results

Initial results from the pivotal Cohort 4 in the C-144-01 clinical study is available for 68 patients with two radiological assessments, as determined by investigator. Primary endpoint for the C-144-01 Cohort 4 study is ORR by independent review committee and secondary endpoint is ORR by investigator. Lifileucel shows a 32.4% overall response rate (1 complete response and 21 partial responses, 2 of which are yet to be confirmed with follow up visits) and a disease control rate of 72.1% as of the data cut off of 16 Mar 2020. This data is consistent with what was noted in Cohort 2 at 6 months of median study follow up. The ORR was 33% as reported in SITC (Free SITC Whitepaper) 2018 abstract.

The Cohort 4 metastatic melanoma patients have a similar patient characteristic profile to Cohort 2 with high baseline disease burden. They have progressed on multiple prior therapies, including anti-PD-1 and BRAF/MEK inhibitors. The adverse event profile was consistent with Cohort 2 and with the underlying advanced disease, lymphodepletion and IL-2 regimens. Cohort 4 dosed a total of 89 patients, and additional updates on Cohort 4 will be presented at upcoming medical meetings. Iovance remains on track to submit a biologics licensing application (BLA) for lifileucel in late 2020.

Updated Cohort 2 Results

Updated results from Cohort 2 will be presented at the ASCO (Free ASCO Whitepaper)20 Virtual Scientific Program during an oral abstract session titled, "Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies." In this Cohort 2 data, lifileucel shows a 36.4% overall response rate (2 complete responses and 22 partial responses) and a disease control rate of 80% (n=66) as assessed by investigators. Median duration of response (DOR) was not reached at 18.7 months of median study follow up (2.2 to 26.9+ months). Durable responses have been observed across a wide age range in metastatic melanoma patients who have received prior anti-CTLA-4 and BRAF targeted treatments, regardless of BRAF mutation status, and equally in patients with PD-L1 high and low status.

The Cohort 2 melanoma patients are heavily pretreated with high baseline disease burden. They have progressed on multiple prior therapies (3.3 mean prior therapies), including anti-PD-1 and BRAF/MEK inhibitors. The adverse event profile was consistent with the underlying advanced disease, lymphodepletion and IL-2 regimens.

The oral abstract session at ASCO (Free ASCO Whitepaper)20 will be available on demand in the ASCO (Free ASCO Whitepaper) Meeting Library at View Source Details of the presentation are as follows:

Title: Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies

Authors: Amod Sarnaik, et al.

Session Title: Melanoma/Skin Cancers

Session Type: Oral Abstract Session

Abstract Number: 10006

Location: ASCO (Free ASCO Whitepaper)20 Virtual Scientific Program at View Source

Date/Time: available for on-demand viewing starting at 8:00am ET on May 29, 2020

Furthermore, Iovance will provide results from Cohort 4 as well as Cohort 2 of the C-144-01 study in metastatic melanoma as part of the BLA package. Based on the pooled analysis of Cohort 2 plus 4 (n=134), the overall response rate was 34.3%, including three complete responses, 43 partial responses (two of which are yet to be confirmed with follow up visits) and a disease control rate of 76.1%. Median DOR was not reached at 10.6 months of median study follow up.

Bellicum to Participate in Two Upcoming Virtual Investor Conferences

On May 27, 2020 Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, reported that management will participate in two upcoming virtual investor conferences (Press release, Bellicum Pharmaceuticals, MAY 27, 2020, View Source [SID1234558562]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details:

Jefferies Virtual Healthcare Conference
Date/Time: Wednesday, June 3, 2020 at 4:00 p.m. EDT
Format: Fireside Chat

Investor Summit Virtual Summer Summit
Date/Time: Wednesday, June 10, 2020 at 3:20 p.m. EDT
Format: Presentation

Live webcasts of the fireside chat and presentation may be accessed from the Events & Presentation section of the Bellicum website. An archived version of each webcast will be available for replay immediately following the event.

Biodesix Presents Numerous Research Findings at ATS, ASCO, and AACR Virtual Conferences

On May 27, 2020 Biodesix, Inc., a leading diagnostic company in lung disease, recently published three clinical research abstracts, which reported valuable new information regarding treatment of patients in the lung cancer continuum of care (Press release, Biodesix, MAY 27, 2020, View Source [SID1234558580]). The data from these abstracts will be presented as e-posters at the virtual annual meetings of the American Thoracic Society (ATS), American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), and American Association for Cancer Research (AACR) (Free AACR Whitepaper).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract #A4465: First Look at the Distribution of Risk of Malignancy Pre and Post-Test Using a Blood-Based Biomarker in Patients with Pulmonary Nodules in a Real-World Observational Study
Published: ATS, American Journal of Respiratory and Critical Care Medicine, May 1
An abstract published by Michael Pritchett, DO, MPH of Pinehurst Medical Clinic reports findings from the ORACLE observational study (NCT03766958), which highlights the use of the Nodify XL2 test. The data suggest that using blood-based biomarkers integrated with clinical risk factors to calculate risk of malignancy for solitary pulmonary nodules may be important in helping guide physicians in determining treatment strategy, including potentially reducing performance of invasive procedures on benign nodules. Dr. Pritchett will present the data in a webinar on June 18.

Abstract #9545: Real-World Performance of Blood-Based Host Immune Profiling in First-line Immunotherapy Treatment in Advanced Stage Non-Small Cell Lung Cancer
Published: ASCO (Free ASCO Whitepaper) Virtual Annual Meeting, Journal of Clinical Oncology, May 13
An abstract published by R. Brian Mitchell, M.D. of Virginia Cancer Institute reports data from the interim analysis of the ongoing INSIGHT clinical study (NCT03289780). The data suggest that blood-based host immune profiling can provide clinically significant information to predict outcomes and guide treatment choices made by physicians for patients with advanced non-small cell lung cancer eligible for immune checkpoint inhibitor therapy. This abstract will be available as an e-poster at ASCO (Free ASCO Whitepaper)’s upcoming annual meeting. Wallace Akerley, M.D. of Huntsman Cancer Institute will present the data in a webinar on June 3.

Abstract # 3101 / 11: Utility of a New Targeted Next Generation Sequencing Test for Liquid Biopsy Samples from Patients with NSCLC
Published: AACR (Free AACR Whitepaper) Virtual Annual Meeting II, May 15
In an abstract published by Hestia Mellert, Ph.D., of Biodesix, data suggest that a newly-developed blood-based next generation sequencing test method supports the usefulness of molecular detection of actionable and emerging biomarkers in a liquid biopsy. The abstract will be available as an e-poster at AACR (Free AACR Whitepaper)’s Virtual Annual Meeting II. Dr. Mellert will present the data from the poster in a webinar on June 25.

"Acceptance of these abstracts, especially at three of the most important events in oncology and pulmonology, is extremely meaningful for Biodesix. It is a testament to the value of our research, and our commitment to delivering actionable results," said Scott Hutton, Chief Executive Officer of Biodesix. "The data presented in these abstracts represent another step for Biodesix in solving complex diagnostic challenges in lung disease, and we’re tremendously proud to share that."

Deciphera Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference

On May 27, 2020 Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial biopharmaceutical company addressing key mechanisms of tumor drug resistance, reported that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies 2020 Healthcare Conference on Wednesday, June 3, 2020 at 2:00 PM ET. The conference will be held in a virtual meeting format (Press release, Deciphera Pharmaceuticals, MAY 27, 2020, View Source [SID1234558529]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

Dynavax Technologies Announces Closing of $80.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

On May 27, 2020 Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, reported the closing of its previously announced underwritten public offering of 16,100,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,100,000 shares, at a price to the public of $5.00 per share (Press release, Dynavax Technologies, MAY 27, 2020, View Source [SID1234558545]). The gross proceeds to Dynavax from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Dynavax, were approximately $80.5 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen, Evercore ISI and William Blair acted as joint book-running managers for the offering. H.C. Wainwright & Co. acted as co-manager for the offering.

Dynavax anticipates using the net proceeds from the offering to fund activities associated with the ongoing commercialization of HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], to advance its CpG 1018 vaccine platform, including any scale up efforts in support of a potential COVID-19 vaccine by Dynavax and its collaborators, and for general corporate purposes, including working capital.

The securities described above were offered by Dynavax pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with and became effective by rule of the Securities and Exchange Commission (SEC) on April 30, 2020. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website located at View Source Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained by contacting: Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 Attention: Prospectus Department, by telephone at (833) 297-2926, or by email at [email protected]; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, New York, NY 10055, by telephone at (888) 474-0200 or by email at [email protected]; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.